PDF Download

Significant strengthening of the patent protection for the sepsis drug candidate Adrecizumab

21.07.2015

Deutsche Biotech Innovativ AG ("DBI") has significantly strengthened the patent protection for its main drug candidate Adrecizumab. The biotechnology company based near Berlin has received the notice of allowance from the United States Patent and Trademark Office (USPTO) for the key patent, which provides comprehensive protection in the treatment of sepsis, shock and systemic inflammatory response syndrome (SIRS) by the drug candidate Adrecizumab.

Hennigsdorf, 21 July 2015 – Deutsche Biotech Innovativ AG ("DBI") has significantly strengthened the patent protection for its main drug candidate Adrecizumab. The biotechnology company based near Berlin has received the notice of allowance from the United States Patent and Trademark Office (USPTO) for the key patent, which provides comprehensive protection in the treatment of sepsis, shock and systemic inflammatory response syndrome (SIRS) by the drug candidate Adrecizumab. 

Following the granting of essential patents for Adrecizumab within the European Union in 2014, the DBI's business is now comprehensively protected in the most important markets until the year 2032 at the very least. DBI has therefore reached another strategically important milestone on the path towards strengthening its market position in the area of sepsis treatment.

"The notice of allowance in relation to the US patent is a key component of our strategic patent portfolio and ensures effective market protection for our first-in-class agent for the treatment of sepsis," commented DBI board member Dr. Bernd Wegener.


About Adrecizumab

Adrecizumab is a humanised antibody and the first therapeutic agent which stabilises the entire body in the case of severe sepsis, since it does not completely block the bioactivity of the body's own peptide hormone Adrenomedullin (ADM), but balances it to a beneficial level. Adrecizumab is designed for the causal and safe treatment of sepsis patients. Following the highly successful process and the promising results of the preclinical studies of safety and efficacy, DBI is currently preparing for the clinical phase I study, expected to start at the end of 2015.

For further information please contact:

Daten­schutz­ein­stellungen

Diese Webseite nutzt externe Komponenten, wie z.B. Videos, Diagramme oder Analysewerkzeuge, welche alle dazu genutzt werden können, Daten über Ihr Verhalten zu sammeln. Dabei werden von den externen Komponenten ggf. auch Cookies gesetzt. Die Einwilligung zur Nutzung der Komponenten können Sie jederzeit widerrufen.
Mehr dazu in unsererer Datenschutzerklärung